|
Q2 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q1 FY2024
As of Mar 31, 2024
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Trade and other receivables | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accrued expenses and other payables | ||||||||||||||||||||
| Other payables - related parties | ||||||||||||||||||||
| Due to related parties | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Deficit | ||||||||||||||||||||
| Common stock - par value $0.001; 75,000,000 shares authorized, 37,415,902 and 55,125,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders' Deficit | ||||||||||||||||||||
Loading...
